We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
-1.51%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$393M
AUM Growth
+$25.3M
Cap. Flow
+$32.9M
Cap. Flow %
8.36%
Top 10 Hldgs %
80.79%
Holding
223
New
14
Increased
85
Reduced
52
Closed
29

Top Buys

Rank Stock Value
1
MBB icon
iShares MBS ETF
MBB
+$10.8M
2
VMBS icon
Vanguard Mortgage-Backed Securities ETF
VMBS
+$10.2M
3
MCRB icon
Seres Therapeutics
MCRB
+$1.62M
4
VUZI icon
Vuzix
VUZI
+$1.34M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.16M

Top Sells

Rank Stock Value
1
OUST icon
Ouster
OUST
+$1.06M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.02M
3
TVTX icon
Travere Therapeutics
TVTX
+$897K
4
ADCT icon
ADC Therapeutics
ADCT
+$633K
5
RBOT
Vicarious Surgical
RBOT
+$548K

Sector Composition

Rank Sector Weight
1 Real Estate 18.05%
2 Healthcare 12.08%
3 Technology 1.59%
4 Financials 1.03%
5 Industrials 0.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VUZI icon
26
Vuzix
VUZI
$188M
$1.05M 0.27%
+100,000
New +$1.34M
PBYI icon
27
Puma Biotechnology
PBYI
$434M
$1.04M 0.26%
148,500
+108,500
+271% +$812K
CLPT icon
28
ClearPoint Neuro
CLPT
$454M
$1.02M 0.26%
57,500
+7,500
+15% +$141K
ARAY icon
29
Accuray
ARAY
$30.8M
$988K 0.25%
250,000
+15,000
+6% +$59.5K
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$987K 0.25%
65,000
+15,000
+30% +$234K
ARNA
31
DELISTED
Arena Pharmaceuticals Inc
ARNA
$983K 0.25%
16,500
+9,000
+120% +$532K
MFA
32
MFA Financial
MFA
$960M
$980K 0.25%
53,609
+17,069
+47% +$317K
TCRR
33
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$962K 0.24%
113,000
+72,000
+176% +$1.02M
TRIL
34
DELISTED
Trillium Therapeutics Inc.
TRIL
$957K 0.24%
54,500
+24,500
+82% +$286K
COOP
35
DELISTED
Mr. Cooper
COOP
$938K 0.24%
22,794
+3,655
+19% +$138K
ACRS icon
36
Aclaris Therapeutics
ACRS
$793M
$918K 0.23%
51,000
+14,000
+38% +$224K
CLDX icon
37
Celldex Therapeutics
CLDX
$2.77B
$918K 0.23%
17,000
-8,000
-32% -$375K
CYBE
38
DELISTED
Cyberoptics Corp
CYBE
$890K 0.23%
25,000
– –
SYRE icon
39
Spyre Therapeutics
SYRE
$8.7B
$875K 0.22%
4,400
+700
+19% +$122K
ARQT icon
40
Arcutis Biotherapeutics
ARQT
$3.56B
$848K 0.22%
35,500
+22,000
+163% +$502K
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.82B
$832K 0.21%
9,000
-5,000
-36% -$385K
GILD icon
42
Gilead Sciences
GILD
$167B
$803K 0.2%
11,500
-300
-3% -$21.1K
KPTI icon
43
Karyopharm Therapeutics
KPTI
$216M
$792K 0.2%
9,067
+3,634
+67% +$377K
INSM icon
44
Insmed
INSM
$23.5B
$785K 0.2%
28,500
+4,500
+19% +$118K
PRCT icon
45
Procept Biorobotics
PRCT
$1.09B
$763K 0.19%
+20,000
New +$768K
SAFE
46
Safehold
SAFE
$1.22B
$759K 0.19%
6,221
+5,341
+607% +$644K
AXSM icon
47
Axsome Therapeutics
AXSM
$11.8B
$758K 0.19%
23,000
+11,000
+92% +$429K
IOVA icon
48
Iovance Biotherapeutics
IOVA
$2.23B
$752K 0.19%
30,500
-3,000
-9% -$70.7K
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$741K 0.19%
92,402
– –
MRK icon
50
Merck
MRK
$315B
$732K 0.19%
9,750
-2,250
-19% -$171K
1
2
3 4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, AlphaCentric Advisors held 223 positions worth $393M, up 6.9% from $368M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

AlphaCentric Advisors deployed $32.9M of net new capital in Q3 2021, opening 14 new positions and adding to 85 existing holdings. Its largest new stake was Seres Therapeutics: 8,275 shares worth $1.15M.

By sector, the portfolio is most concentrated in Real Estate at 18% of assets, down from 19% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $1.02M trimmed.

  • AlphaCentric Advisors's largest Q3 2021 buy was Seres Therapeutics: 8,275 shares worth $1.15M.
  • AlphaCentric Advisors added most to iShares MBS ETF in Q3 2021, an estimated $10.8M increase.
  • AlphaCentric Advisors's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.02M.
  • AlphaCentric Advisors fully exited Ouster in Q3 2021, selling an estimated $1.06M.
  • AlphaCentric Advisors's ten largest holdings make up 81% of its $393M portfolio in Q3 2021.
  • AlphaCentric Advisors opened 14 new positions and closed 29 in Q3 2021.
  • AlphaCentric Advisors's portfolio value rose 6.9% quarter-over-quarter to $393M.

Based on AlphaCentric Advisors's 13F filing for Q3 2021, filed 9 Mar 2022.